Acquired by RXRX Cyclica has been acquired by Recursion (Nasdaq: RXRX), indicating strategic expansion and potential cross-sell opportunities with Recursion's platform and customers.

Small team, nimble With 2-10 employees, the company operates lean, suggesting a high willingness to partner with scalable, plug-and-play solutions that can quickly integrate and add value without heavy onboarding.

Financial runway Reported revenue between one and ten million and total funding of twenty-six million imply a startup with room for growth initiatives and a priority on cost-effective, high-ROI tools.

Biotech AI angle Operating in biotechnology research and leveraging tech like TensorFlow, Cyclica aligns with AI-driven R&D capabilities, presenting opportunities for AI-powered data analysis, modeling, and automation offerings.

Competitive landscape Industry mentions of link-in-bio and creator platforms in recent news highlight a competitive market; potential upsell for branding, customer acquisition, and affiliate or partner ecosystems to strengthen market position.